Matthew A Gubens - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Matthew A Gubens

Showing results (31-40 of 59) with videos related to

Pageof 6

Sort By:

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 13, 2024

Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium SocietyHenry S Park, Andreas Rimner, Arya Amini, et al.

JTO Clinical and Research Reports|March 7, 2023

Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 23, 2024

American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic RadiotherapyArya Amini, Vlad G Zaha, Eman Hamad, et al.

Cell Reports|April 7, 2015

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.

Journal of the American Geriatrics Society|October 6, 2021

Changes in older adults' life space during lung cancer treatment: A mixed methods cohort studyMelisa L Wong, Ying Shi, Alexander K Smith, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.

The Lancet. Respiratory Medicine|June 27, 2025

Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.

Nature Medicine|July 10, 2023

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.

Pageof 6

Search research articles

Showing results (31-40 of 59) with videos related to

Sort By:

Pageof 6

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 13, 2024

JTO Clinical and Research Reports|March 7, 2023

Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 23, 2024

American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic RadiotherapyArya Amini, Vlad G Zaha, Eman Hamad, et al.

Cell Reports|April 7, 2015

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.

Journal of the American Geriatrics Society|October 6, 2021

Changes in older adults' life space during lung cancer treatment: A mixed methods cohort studyMelisa L Wong, Ying Shi, Alexander K Smith, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020

The Lancet. Respiratory Medicine|June 27, 2025

Nature Medicine|July 10, 2023

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.

Pageof 6